$5.49
arrow_drop_down3.85%Performance History
| Key Stats | |
|---|---|
| Open | $5.69 |
| Prev. Close | $5.71 |
| EPS | -0.43 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $816.63M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 5.56 | 5.76 |
| 52 Week Range | 4.71 | 12.43 |
| Ratios | |
|---|---|
| P/B Ratio | 1.95 |
| Revenue | $175.51M |
| Operating M. % | -13.06% |
| Earnings | $0.00 |
| Earnings Growth % | 27.88% |
| EBITDA Margin % | -26.78% |
| ROEÂ % | -16.69% |
| EPS | -0.43 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
Correlated Companies
About Aurinia Pharmaceuticals (AUPH)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Peter S. Greenleaf M.B.A.
- Headquarters
- Victoria
- Employees
- 300
- Exchange
- NASDAQ
Keep an eye on Aurinia Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Aurinia Pharmaceuticals 's (AUPH) price per share?
The current price per share for Aurinia Pharmaceuticals (AUPH) is $5.49. The stock has seen a price change of -$0.22 recently, indicating a -3.85% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Aurinia Pharmaceuticals (AUPH)?
For Aurinia Pharmaceuticals (AUPH), the 52-week high is $12.43, which is 126.41% from the current price. The 52-week low is $4.71, the current price is 16.56% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Aurinia Pharmaceuticals (AUPH) a growth stock?
Aurinia Pharmaceuticals (AUPH) has shown an average price growth of 0.41% over the past three years. It has received a score of 23 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aurinia Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Aurinia Pharmaceuticals (AUPH) stock price performance year to date (YTD)?
As of the latest data, Aurinia Pharmaceuticals (AUPH) has a year-to-date price change of -37.19%. Over the past month, the stock has experienced a price change of 1.29%. Over the last three months, the change has been 1.67%. Over the past six months, the figure is -37.19%. Looking at a longer horizon, the five-year price change stands at -14.75%.
Is Aurinia Pharmaceuticals (AUPH) a profitable company?
Aurinia Pharmaceuticals (AUPH) has a net income of -$78.02M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 91.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -13.06% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $175.51M, with a revenue growth rate of 30.95%, providing insight into the company's sales performance and growth. The gross profit is $161.36M. Operating income is noted at -$83.31M. Furthermore, the EBITDA is -$47M.
What is the market capitalization of Aurinia Pharmaceuticals (AUPH)?
Aurinia Pharmaceuticals (AUPH) has a market capitalization of $816.64M. The average daily trading volume is 1.18M, indicating the stock's liquidity and investor engagement.
News
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.